register

News & Trends - Pharmaceuticals

Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment

Health Industry Hub | March 22, 2021 |

Pharma News: Australian clinical-stage drug development company Noxopharm announced that the IONIC-1 trial supported by Noxopharm and Bristol Myers Squibb (BMS) received final ethics approval to start recruiting patients.

The IONIC-1 trial is a Phase 1b trial in approximately 30 cancer patients, combining Veyonda with the BMS immune checkpoint inhibitor, Opdivo (nivolumab), for the treatment of a range of tumour types.

Immune checkpoint inhibitors (ICI) such as nivolumab have had spectacular results in some patients with a small number of cancer types, but remain inactive in most forms of cancer. The IONIC-1 study will
explore whether adding Veyonda to ICI therapy will overcome tumor resistance to nivolumab, making more cancer types responsive to nivolumab.

The ICI market is a multi-billion-dollar market predicted by market analysts to generate sales of up to US$45 billion by 2025 through strong year-on-year growth. Increasing the number of cancer types that respond to ICI therapy would expand the market even more, leaving any company with the technology to help achieve that goal in a highly valuable position. The ICI market currently is dominated by two major global pharmaceutical companies, one of which is Bristol Myers Squibb.

Medical Oncologist Professor de Souza and Principal Investigator of this trial said “We’re now ready to begin recruiting patients into IONIC-1. The potential of this trial to bring effective checkpoint inhibitor treatment to a broader range of patients is an exciting prospect. If we’re able to enhance the effect of BMS’s nivolumab with Veyonda, this will bring some truly
life-changing treatment to cancer patients’ lives and will change the way that cancer is treated worldwide.”

The IONIC-1 trial will commence immediately. There will be two cohorts of patients, one cohort comprising patients who have not had previous Opdivo treatment because they have cancers considered unsuitable for ICI use, and the other cohort will be patients whose cancers have displayed resistance to Opdivo treatment.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.